Engineering News

GPC Biotech slashes 44 pct of workforce to survive
Thu Nov 15, 2007 5:01am EST

FRANKFURT, Nov 15 (Reuters) - GPC Biotech is cutting 44 percent of its workforce, or 103 staff, the German biotech company said on Thursday, after its key prostate cancer drug hope satraplatin failed in a clinical trial.

The move affects 60 employees in Munich and 43 U.S. staff in Princeton, New Jersey, the company said, adding the remaining workforce will be 56 in Munich and 58 in Princeton after the completion of the shutdown of its Waltham, Massachusetts facility in a few weeks. The downsizing was widely expected after the satraplatin failure. GPC shares were up 1.9 percent at 3.17 euros at 0957 GMT.

Source: Reuters

Engineering News Archive

 
// CAREER RESOURCES

Applicant Procedures
Job Seekers
Resume Help
Professional Organizations
Engineering Career Information
Engineering Colleges

// WHAT WE DO
Recruiters for
Professionals in the Chemical
& Pharmaceutical Industries
We recruit exclusively for Engineers and Operations/Maintenance Management Personnel in the following areas:
Specialty chemicals
Bulk chemicals
Commodity Chemicals
Petrochemicals
Fine chemicals
Agrochemicals
Industrial gases
Surfactants
Fertilizers
Solvents
Coatings
Polymers
Pharmaceuticals
Refinery
Career Center | FAQs | Privacy
SESI Corporate Headquarters (954)755-3121 ext 109
© Search Enterprises, Inc. All rights reserved.
Industry News Career Center FAQs Submit a Job About Search Enterprises Submit a Resume Candidates Job Opportunities Search Enterprises Home